Company news
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) news
Every Acadia Pharmaceuticals Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the Eu...
August 24, 2026
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
July 30, 2026
Acadian Asset Management : Reports Financial and Operating Results for the Second Quarter Ended June 30, 2026 (Presentation)
July 30, 2026
Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
July 20, 2026
Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
July 15, 2026
Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
July 6, 2026
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
June 26, 2026
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
May 6, 2026
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Followi...
April 30, 2026
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
April 17, 2026
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
April 15, 2026
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
April 7, 2026
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 12, 2026
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
March 3, 2026
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett...
March 2, 2026
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
February 25, 2026
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
February 4, 2026
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
February 2, 2026
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
January 13, 2026
Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
December 18, 2025
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide fo...
December 12, 2025
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference
November 20, 2025
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
November 5, 2025
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
October 28, 2025
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 15, 2025
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s...
October 2, 2025
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Di...
September 24, 2025
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett S...
September 12, 2025
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 8, 2025
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
August 25, 2025
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
August 6, 2025
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
August 5, 2025
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
August 4, 2025
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
July 23, 2025
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
June 25, 2025
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin...
June 9, 2025
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
June 5, 2025
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
May 29, 2025
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
May 27, 2025
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
May 16, 2025
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
May 7, 2025
Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference
May 5, 2025
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025
April 23, 2025
Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Publish...
March 5, 2025
Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study
March 3, 2025
Acadia Pharmaceuticals to Participate in the TD Cowen’s 45th Annual Health Care Conference
February 27, 2025
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
February 26, 2025
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 12, 2025
Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of ...
January 14, 2025
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025